The GLP-1 Effect: How Ozempic Is Rewriting the Entire Food Industry

Last updated: March 28, 2026 · 12 min read

Table of contents

1. The numbers are wild
2. What people stop buying
3. The snack industry panic
4. What people start buying
5. Restaurants and the shrinking plate
6. The honest section
7. FAQ
8. Food after Ozempic

The global food industry is worth over $8 trillion. And right now, a single class of drugs is forcing it to restructure. Morgan Stanley estimates GLP-1 medications will reduce U.S. calorie consumption by 1.5-2.5% by 2035 — enough to wipe tens of billions in annual revenue from grocery chains, snack conglomerates, and fast food empires. One in four American households already has someone on these drugs, and they’re spending 5.3% less on groceries and 8% less at restaurants.

GLP-1 receptor agonists — sold as Ozempic, Wegovy, Mounjaro, and Zepbound — are medications that mimic a gut hormone signaling fullness to the brain. Originally developed for type 2 diabetes, they now reduce caloric intake by roughly 21%, triggering the largest shift in American eating behavior since the low-fat craze of the 1990s.

The numbers are wild

I keep coming back to that 21% number. GLP-1 users eat a fifth less food. Not because of willpower or a new diet trend — because a drug is telling their brain they’re full.

A Cornell University study published in December 2025 tracked household purchasing data across thousands of GLP-1 users and found the effects kick in fast and stick around:

• Grocery spending drops 5.3% within the first 6 months
• Higher-income households see drops over 8%
• Units per shopping trip fall 3-5%
• Effects persist for at least a year among continued users
• Monthly grocery spending drops up to 31% for some users

That last number — 31% — is from the most affected users. Even the average 5.3% is enormous when you multiply it across 23% of American households. We’re talking billions of dollars in annual grocery sales that just aren’t happening anymore.

And it’s going to get bigger. Novo Nordisk announced 35-50% price cuts for Ozempic and Wegovy in 2027, oral versions are coming, and Costco is offering access at around $499/month.

What people stop buying

Not everything drops equally. The Cornell study and Oklahoma State University research identified clear winners and losers by food category.

The pattern is clear: ultra-processed, high-calorie, impulse-driven foods take the biggest hit. Users describe snacking urges as “completely eliminated.” Not reduced — eliminated. That’s a fundamentally different thing than a diet where you’re resisting temptation. GLP-1 users aren’t resisting. They just don’t want the chips.

This connects to something worth understanding: the way ultra-processed foods are engineered to override satiety signals. Research into the controversy around seed oils and how ultra-processed food is literally addictive shows that these products are designed to make you eat past fullness. GLP-1 drugs seem to break that cycle pharmacologically, which is part of why the behavior changes are so dramatic.

The snack industry panic

Packaged food company stock prices have been falling while pharmaceutical stocks rise. That chart tells you everything.

Nestlé, Danone, General Mills, and Coca-Cola have all started launching “GLP-1 friendly” products — smaller portions, higher fiber, more protein. Coca-Cola pushed mini cans into convenience stores. Smoothie King created a GLP-1 menu with protein-boosted smoothies. Starbucks started offering high-protein milk drinks.

80% of GLP-1 users say they’ll pay a premium for foods with health benefits, according to industry surveys. That’s a fascinating shift: people eating less but willing to pay more per item. The total grocery basket shrinks, but the per-unit value goes up — if the product delivers on nutrition.

The companies most at risk are the ones built entirely on impulse purchases and addictive flavor profiles. If your business model depends on people eating an entire bag of chips in one sitting, you have a GLP-1 problem. And that problem is growing by millions of new prescriptions per quarter.

What people start buying

The story isn’t just about decline. Some categories are growing because of GLP-1 drugs.

• Yogurt (especially high-protein Greek yogurt) — modest increase
• Fresh fruit — modest increase
• Nutrition/protein bars — modest increase
• Meat snacks (jerky, biltong) — modest increase

The pattern: when you eat less, you care more about what you eat. GLP-1 users are shifting toward protein-rich, nutrient-dense foods. They’re buying less volume but choosing higher-quality items. Fresh produce, lean protein, foods that deliver maximum nutrition per calorie.

This is genuinely good news for local food producers, vertical farms, and anyone growing fresh produce. If the market is shifting toward “fewer calories, better quality,” that’s a tailwind for the kind of food that urban farming produces — fresh, local, nutrient-dense greens and herbs that can command a price premium from consumers who are buying less but buying better.

It also connects to the growing concern about food waste reduction technology — because when people buy less food overall, the industry needs to get smarter about waste at every stage of the supply chain. And when people care more about nutrient density per calorie, questions about whether hydroponic food is actually healthy start to matter more.

Restaurants and the shrinking plate

Restaurant spending among GLP-1 users dropped about 8%, driven by reduced frequency rather than switching to cheaper options. People aren’t trading down from Olive Garden to McDonald’s — they’re going out less because they’re not as hungry.

Restaurants are adapting. Olive Garden is testing reduced portion sizes. Some chains are introducing “lighter” menu sections that aren’t diet menus in the traditional sense — they’re built around what GLP-1 users actually want to eat: smaller plates of higher-quality protein with vegetables.

Fast food gets hit harder than sit-down restaurants. That makes intuitive sense — fast food is built on convenience and impulse. When the impulse goes away, the convenience matters less. Nobody takes Ozempic and then craves a drive-through cheeseburger at 10pm.

Coffee shops also saw a drop, which I found surprising until I thought about it. Most coffee shop spending isn’t black coffee — it’s $7 frappuccinos with whipped cream and pastry cases full of muffins. GLP-1 kills the pastry case.

The honest section

I’ve painted a pretty dramatic picture so far, so here’s where I pump the brakes and acknowledge the complications. Because there are real ones.

Side effects are significant. GLP-1 drugs cause nausea in roughly 40% of users, along with vomiting, diarrhea, and constipation. Some users develop gastroparesis (stomach paralysis). Reports of pancreatitis and thyroid concerns are being tracked in long-term studies. These aren’t minor inconveniences — they’re the reason roughly 30-50% of patients stop taking the drugs within the first year.

Access is wildly unequal. Without insurance, Ozempic costs $900-1,300/month. Even Costco’s $499 option is out of reach for most households. The people who most need help with diet-related disease are the least likely to afford these drugs. Right now, GLP-1 medications are disproportionately used by wealthier, insured Americans — which means the food industry shifts we’re seeing are driven by high-income households, not the population at large.

The demand shift may not be permanent. Most of the spending data comes from users still on the drugs. When people stop taking GLP-1 medications, appetite rebounds in roughly two-thirds of cases. If adherence stays at current levels — and prices don’t drop enough to expand access broadly — the structural shift could plateau well short of the projections Morgan Stanley and Goldman Sachs are modeling.

FAQ

Food after Ozempic

Here’s what I think is actually happening, if you zoom out far enough: GLP-1 drugs are doing what decades of nutrition education, food labeling, and public health campaigns couldn’t. They’re reducing consumption of ultra-processed food — not through information or willpower, but through pharmacology.

Whether you think that’s a good thing or a dystopian thing probably depends on your perspective. A drug that makes people eat less junk food, buy more fresh produce, and reduce their caloric intake by 21% will save lives. It will also shrink grocery store revenue, put pressure on snack companies, and fundamentally change how the food industry operates.

For anyone in the food system — farmers, food tech companies, restaurants, grocers — the GLP-1 effect isn’t a temporary trend. It’s a structural shift. The question isn’t whether it’ll change the food industry. It already has. The question is how fast and how far.

Written by Lorenzo Russo — founder of FoodLore. He has complicated feelings about a drug that makes Doritos sound unappealing.